Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18715504 | 0.84 | NPC1 (0.88) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL16083145 | 0.84 | NPC1 (0.88) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL16083179 | 0.82 | NPC1 (0.70) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL8374096 | 0.81 | NPC1 (0.66) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL15613309 | 0.81 | SMN1; SMN2 (0.72) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL29952871 | 0.80 | ALDH1A1 (0.70) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL17656858 | 0.80 | RAB9A (0.80) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL25893683 | 0.80 | NPC1 (0.80) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL7844241 | 0.80 | CYP2C19 (0.51) | ALDH1A1POLBLMNASMN1; SMN2MEN1 | |
| SCHEMBL16872915 | 0.80 | SMN1; SMN2 (0.70) | NPC1RAB9AHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | NPC1 3836/4885RAB9A 2229/4885HPGD 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.